Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX

by Hamdy Zawam, Wael Edesa, Sherif Alrefai, Ahmed Abdelhafeez
Published 2018-06-01

ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study

by Hamdy Zawam, Wael Edesa, Sherif Alrefai, Rasha Salama, Ahmed Abdelhafeez
Published 2018-06-01

Role of diffusion MRI in diagnosis of mediastinal lymphoma: initial assessment and response to therapy

by Youssriah Yahia Sabri, Nourhan Mohamed Ewis, Hussam Eldin Hamdy Zawam, Mostafa Ahmed Khairy
Published 2021-08-01

Study of HOTAIR LncRNA in AML patients in context to FLT3-ITD and NPM1 mutations status

by Mona Salah, Hamdy Zawam, Neven Bahaa Fouad, Nohair Soliman, Fatma Abdel Wahab Abdel Maksoud
Published 2021-06-01